Share Price and Basic Stock Data
Last Updated: January 15, 2026, 2:50 am
| PEG Ratio | -5.12 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gufic BioSciences Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹314 and a market capitalization of ₹3,149 Cr. The company reported a steady revenue trend, with sales rising from ₹175 Cr in September 2022 to ₹215 Cr by September 2023. This growth trajectory reflects a compounded increase, showcasing the company’s ability to expand its market presence. While the trailing twelve months (TTM) revenue reached ₹870 Cr, the annual sales for FY 2025 are projected at ₹820 Cr, slightly up from ₹807 Cr in FY 2024. The quarterly sales data indicates some fluctuations, especially with a peak of ₹215 Cr in September 2023 before settling back to ₹202 Cr in December 2023, suggesting seasonality or market dynamics that require further analysis. Overall, Gufic’s sales growth indicates resilience in a competitive pharmaceutical landscape, although external factors such as regulatory changes and pricing pressures could influence future performance.
Profitability and Efficiency Metrics
Gufic BioSciences reported a net profit of ₹54 Cr, with a P/E ratio of 58.0, indicating a premium valuation compared to average industry metrics. The operating profit margin (OPM) stood at 16%, reflecting a stable efficiency in managing costs relative to sales. However, the OPM has shown variability, declining from 19% in FY 2022 to 17% in FY 2025, highlighting potential challenges in cost management or pricing strategies. The return on equity (ROE) for the company was recorded at 12.3%, while the return on capital employed (ROCE) was slightly higher at 13.2%. These figures suggest that while Gufic is generating returns, they are below optimal levels as compared to industry standards, where higher ROE and ROCE ratios are typically expected. The cash conversion cycle (CCC) of 197 days indicates a potential liquidity risk, as longer cycles can affect cash flow and operational efficiency, necessitating closer scrutiny of working capital management.
Balance Sheet Strength and Financial Ratios
Gufic BioSciences’ balance sheet reflects a solid foundation, with total assets amounting to ₹1,170 Cr and total liabilities of ₹1,093 Cr, resulting in a manageable debt-to-equity ratio of 0.51. Borrowings stood at ₹369 Cr, a slight increase from ₹336 Cr in FY 2025, indicating a potential rise in leverage. The company has reserves of ₹619 Cr, which provide a buffer for future investments or downturns. The interest coverage ratio (ICR) of 5.70x suggests that Gufic can comfortably meet its interest obligations, although this has decreased from 9.64x in the previous fiscal year. The price-to-book value (P/BV) ratio is at 5.61x, indicating a premium valuation, which may reflect investor confidence but also suggests that the stock may be overvalued compared to its tangible assets. Overall, while Gufic’s balance sheet exhibits strength, the rising debt levels and decreasing interest coverage raise concerns about future financial flexibility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gufic BioSciences demonstrates a strong commitment from promoters, holding 72.50% of the company. The presence of foreign institutional investors (FIIs) has been minimal at 0.33%, while domestic institutional investors (DIIs) have a slightly more significant stake at 3.66%. This distribution indicates a reliance on promoter support, which can be both a strength and a risk; high promoter holdings often reflect confidence in the company but can also lead to governance concerns if not balanced with public participation. The number of shareholders has decreased from 40,562 in December 2022 to 31,420 by September 2025, suggesting a potential decline in retail interest. This reduction may indicate either a consolidation of shares among larger investors or waning confidence among smaller shareholders. Maintaining a balanced and diversified shareholder base is crucial for long-term stability and growth.
Outlook, Risks, and Final Insight
Gufic BioSciences is well-positioned in the pharmaceutical sector, with a focus on expanding its product portfolio and market reach. The steady growth in revenue and profitability metrics provides a positive outlook, but the company faces several risks. Rising operational costs, as indicated by fluctuating profit margins, and an extended cash conversion cycle could hinder performance. Additionally, the relatively high P/E ratio may deter new investors if earnings do not grow in line with market expectations. The reliance on promoter holdings poses a potential governance risk, especially if public sentiment shifts. To navigate these challenges, Gufic must enhance operational efficiency, diversify its funding sources, and maintain transparent communication with investors. The company’s ability to address these risks while capitalizing on growth opportunities will determine its future trajectory in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 136 Cr. | 108 | 207/84.3 | 30.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,134.75 Cr | 1,122.37 | 52.67 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 175 | 177 | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 |
| Expenses | 142 | 143 | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 |
| Operating Profit | 33 | 34 | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 |
| OPM % | 19% | 19% | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 |
| Interest | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 |
| Depreciation | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 |
| Profit before tax | 27 | 27 | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 |
| Tax % | 26% | 25% | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% |
| Net Profit | 20 | 20 | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 |
| EPS in Rs | 2.08 | 2.10 | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 |
Last Updated: January 1, 2026, 1:46 pm
Below is a detailed analysis of the quarterly data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 230.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Jun 2025) to 230.00 Cr., marking an increase of 3.00 Cr..
- For Expenses, as of Sep 2025, the value is 195.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 195.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Jun 2025) to 36.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Jun 2025) to 16.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 15.00 Cr., marking an increase of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.49. The value appears strong and on an upward trend. It has increased from 1.20 (Jun 2025) to 1.49, marking an increase of 0.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 870 |
| Expenses | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 741 |
| Operating Profit | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 129 |
| OPM % | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 15% |
| Other Income | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | -0 | 4 | 5 |
| Interest | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 32 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 28 |
| Profit before tax | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 74 |
| Tax % | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | |
| Net Profit | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 54 |
| EPS in Rs | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 5.41 |
| Dividend Payout % | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 75.00% | 28.57% | 77.78% | 37.50% | 4.55% | 91.30% | 118.18% | -16.67% | 7.50% | -18.60% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -46.43% | 49.21% | -40.28% | -32.95% | 86.76% | 26.88% | -134.85% | 24.17% | -26.10% |
Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | -10% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 35% |
| 3 Years: | 16% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 619 |
| Borrowings | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 369 |
| Other Liabilities | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 271 |
| Total Liabilities | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
| Fixed Assets | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 495 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 24 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 |
| Other Assets | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 | 747 |
| Total Assets | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
Below is a detailed analysis of the balance sheet data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 619.00 Cr.. The value appears strong and on an upward trend. It has increased from 591.00 Cr. (Mar 2025) to 619.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 369.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 336.00 Cr. (Mar 2025) to 369.00 Cr., marking an increase of 33.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 271.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 232.00 Cr. (Mar 2025) to 271.00 Cr., marking an increase of 39.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 495.00 Cr.. The value appears to be declining and may need further review. It has decreased from 506.00 Cr. (Mar 2025) to 495.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 747.00 Cr.. The value appears strong and on an upward trend. It has increased from 639.00 Cr. (Mar 2025) to 747.00 Cr., marking an increase of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
Notably, the Reserves (619.00 Cr.) exceed the Borrowings (369.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -19.00 | -23.00 | -34.00 | -41.00 | -52.00 | -74.00 | 22.00 | 84.00 | -199.00 | -183.00 | -200.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 |
| Inventory Days | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 |
| Days Payable | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 |
| Cash Conversion Cycle | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 |
| Working Capital Days | 20 | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 |
| ROCE % | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Multicap Fund | 1,480,998 | 0.33 | 52.67 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 1,000,000 | 0.86 | 35.57 | 1,000,000 | 2025-04-22 17:25:34 | 0% |
| ICICI Prudential Smallcap Fund | 446,517 | 0.19 | 15.88 | 441,293 | 2025-12-15 09:10:00 | 1.18% |
| Bank of India Small Cap Fund | 348,463 | 0.63 | 12.39 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 74,008 | 0.02 | 2.63 | N/A | N/A | N/A |
| ICICI Prudential Bharat Consumption Fund | 32,021 | 0.03 | 1.14 | 4,993 | 2025-12-15 09:10:00 | 541.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 6.95 | 8.74 |
| Diluted EPS (Rs.) | 6.95 | 8.74 |
| Cash EPS (Rs.) | 9.05 | 10.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Revenue From Operations / Share (Rs.) | 81.75 | 80.44 |
| PBDIT / Share (Rs.) | 13.93 | 14.76 |
| PBIT / Share (Rs.) | 11.83 | 13.07 |
| PBT / Share (Rs.) | 9.39 | 11.54 |
| Net Profit / Share (Rs.) | 6.95 | 8.59 |
| NP After MI And SOA / Share (Rs.) | 6.95 | 8.59 |
| PBDIT Margin (%) | 17.04 | 18.35 |
| PBIT Margin (%) | 14.47 | 16.24 |
| PBT Margin (%) | 11.48 | 14.33 |
| Net Profit Margin (%) | 8.49 | 10.67 |
| NP After MI And SOA Margin (%) | 8.49 | 10.67 |
| Return on Networth / Equity (%) | 11.58 | 16.17 |
| Return on Capital Employeed (%) | 15.17 | 18.18 |
| Return On Assets (%) | 5.95 | 7.88 |
| Long Term Debt / Equity (X) | 0.21 | 0.28 |
| Total Debt / Equity (X) | 0.51 | 0.59 |
| Asset Turnover Ratio (%) | 0.72 | 0.00 |
| Current Ratio (X) | 1.61 | 1.61 |
| Quick Ratio (X) | 1.05 | 1.08 |
| Inventory Turnover Ratio (X) | 3.93 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 1.43 | 1.12 |
| Dividend Payout Ratio (CP) (%) | 1.10 | 0.93 |
| Earning Retention Ratio (%) | 98.57 | 98.88 |
| Cash Earning Retention Ratio (%) | 98.90 | 99.07 |
| Interest Coverage Ratio (X) | 5.70 | 9.64 |
| Interest Coverage Ratio (Post Tax) (X) | 3.84 | 6.61 |
| Enterprise Value (Cr.) | 3655.21 | 3142.92 |
| EV / Net Operating Revenue (X) | 4.46 | 3.90 |
| EV / EBITDA (X) | 26.16 | 21.23 |
| MarketCap / Net Operating Revenue (X) | 4.12 | 3.52 |
| Retention Ratios (%) | 98.56 | 98.87 |
| Price / BV (X) | 5.61 | 5.33 |
| Price / Net Operating Revenue (X) | 4.12 | 3.52 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Gufic BioSciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has decreased from 10.29 (Mar 24) to 9.05, marking a decrease of 1.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.75. It has increased from 80.44 (Mar 24) to 81.75, marking an increase of 1.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.93. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 13.93, marking a decrease of 0.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.83. This value is within the healthy range. It has decreased from 13.07 (Mar 24) to 11.83, marking a decrease of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.39. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 9.39, marking a decrease of 2.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.35 (Mar 24) to 17.04, marking a decrease of 1.31.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has decreased from 16.24 (Mar 24) to 14.47, marking a decrease of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 11.48. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 11.48, marking a decrease of 2.85.
- For Net Profit Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 15. It has decreased from 16.17 (Mar 24) to 11.58, marking a decrease of 4.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.17. This value is within the healthy range. It has decreased from 18.18 (Mar 24) to 15.17, marking a decrease of 3.01.
- For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 7.88 (Mar 24) to 5.95, marking a decrease of 1.93.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.21, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.51, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has increased from 0.00 (Mar 24) to 0.72, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.61. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.61.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.08 (Mar 24) to 1.05, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.93, marking an increase of 3.93.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 20. It has increased from 1.12 (Mar 24) to 1.43, marking an increase of 0.31.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 20. It has increased from 0.93 (Mar 24) to 1.10, marking an increase of 0.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 98.57. This value exceeds the healthy maximum of 70. It has decreased from 98.88 (Mar 24) to 98.57, marking a decrease of 0.31.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 70. It has decreased from 99.07 (Mar 24) to 98.90, marking a decrease of 0.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.70. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 5.70, marking a decrease of 3.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.84. This value is within the healthy range. It has decreased from 6.61 (Mar 24) to 3.84, marking a decrease of 2.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,655.21. It has increased from 3,142.92 (Mar 24) to 3,655.21, marking an increase of 512.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.90 (Mar 24) to 4.46, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 26.16. This value exceeds the healthy maximum of 15. It has increased from 21.23 (Mar 24) to 26.16, marking an increase of 4.93.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 25, the value is 98.56. This value exceeds the healthy maximum of 70. It has decreased from 98.87 (Mar 24) to 98.56, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 5.61. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 5.61, marking an increase of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
- Net Profit Margin: 8.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.17% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.58% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.84
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 58.2 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Dr. Anu S Auora | Independent Director |
| Mr. Kamal K Seth | Independent Director |
| Mr. Akshya Kumar Mahapatra | Independent Director |
FAQ
What is the intrinsic value of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's intrinsic value (as of 16 January 2026) is ₹359.18 which is 14.03% higher the current market price of ₹315.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,159 Cr. market cap, FY2025-2026 high/low of ₹470/285, reserves of ₹619 Cr, and liabilities of ₹1,268 Cr.
What is the Market Cap of Gufic BioSciences Ltd?
The Market Cap of Gufic BioSciences Ltd is 3,159 Cr..
What is the current Stock Price of Gufic BioSciences Ltd as on 16 January 2026?
The current stock price of Gufic BioSciences Ltd as on 16 January 2026 is ₹315.
What is the High / Low of Gufic BioSciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gufic BioSciences Ltd stocks is ₹470/285.
What is the Stock P/E of Gufic BioSciences Ltd?
The Stock P/E of Gufic BioSciences Ltd is 58.2.
What is the Book Value of Gufic BioSciences Ltd?
The Book Value of Gufic BioSciences Ltd is 62.7.
What is the Dividend Yield of Gufic BioSciences Ltd?
The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.
What is the ROCE of Gufic BioSciences Ltd?
The ROCE of Gufic BioSciences Ltd is 13.2 %.
What is the ROE of Gufic BioSciences Ltd?
The ROE of Gufic BioSciences Ltd is 12.3 %.
What is the Face Value of Gufic BioSciences Ltd?
The Face Value of Gufic BioSciences Ltd is 1.00.